{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:22:16Z","timestamp":1792848136135,"version":"4.5.0"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Central nervous system tumors represent the leading cause of cancer-related mortality in children. Conventional therapies of surgery, radiation, and cytotoxic chemotherapy have insufficient efficacy for some pediatric CNS tumors and are associated with significant morbidity, prompting an ongoing need for novel treatment approaches. Identification of molecular alterations driving tumorigenesis has led to a rising interest in developing targeted therapies for these tumors. The present narrative review focuses on recent progress in targeted therapies for pediatric CNS tumors. We outline the key implicated cellular pathways, discuss candidate molecular therapies for targeting each pathway, and present an overview of the clinical trial landscape for targeted therapies in pediatric CNS tumors. We then discuss challenges and future directions for targeted therapy, including combinatorial approaches and real-time drug screening for personalized treatment planning.<\/jats:p>","DOI":"10.3389\/fonc.2025.1504803","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:24:17Z","timestamp":1740727457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeted therapy in pediatric central nervous system tumors: a review from the National Pediatric Cancer Foundation"],"prefix":"10.3389","volume":"15","author":[{"given":"Benjamin I.","family":"Siegel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhumallikarjun","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akul","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Klawinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene I.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou059","article-title":"Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00558","article-title":"Phase II trial of dabrafenib plus trametinib in relapsed\/refractory BRAF V600-mutant pediatric high-grade glioma","volume":"41","author":"Hargrave","year":"2023","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"21623","DOI":"10.1038\/s41598-023-48774-2","article-title":"Tazemetostat in the therapy of pediatric INI1-negative Malignant rhabdoid tumors","volume":"13","author":"Vejmelkova","year":"2023","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7040880","article-title":"Targeting the hedgehog pathway in pediatric medulloblastoma","volume":"7","author":"Huang","year":"2015","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12885-024-11820-x","article-title":"LOGGIC\/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration","volume":"24","author":"van Tilburg","year":"2024","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17040","DOI":"10.1038\/sigtrans.2017.40","article-title":"Targeting cellular pathways in glioblastoma multiforme","volume":"2","author":"Pearson","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-018-0019-5","article-title":"Novel-smoothened inhibitors for therapeutic targeting of naive and drug-resistant hedgehog pathway-driven cancers","volume":"40","author":"Li","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not154","article-title":"Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas - A Pediatric Brain Tumor Consortium study","volume":"16","author":"Gururangan","year":"2014","journal-title":"Neuro-Oncology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor091","article-title":"A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma","volume":"13","author":"Kreisl","year":"2011","journal-title":"Neuro Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e28787","DOI":"10.1002\/pbc.28787","article-title":"A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma","volume":"68","author":"Wright","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.167","article-title":"Trls-14. Pnoc022 report: A combination therapy trial using an adaptive platform design for patients with diffuse midline glioma at initial diagnosis, post-radiation therapy, or progression","volume":"26","author":"Kline","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03641-2","article-title":"A phase I\/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)","volume":"149","author":"DeWire","year":"2020","journal-title":"J Neurooncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discovery"},{"key":"B21","doi-asserted-by":"publisher","first-page":"vdac143","DOI":"10.1093\/noajnl\/vdac143","article-title":"Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy","volume":"4","author":"Gardner","year":"2022","journal-title":"Neurooncol Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox109","article-title":"Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma","volume":"19","author":"Kieran","year":"2017","journal-title":"Neuro Oncol"},{"key":"B23","unstructured":"A phase 2 Study of Dabrafenib (NSC763760) With Trametinib (NSC763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) [Internet]\n          \n          2019"},{"key":"B24","unstructured":"A Phase 3 Randomized Study of Selumetinib Versus Carboplatin\/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) [Internet]\n          \n          2019"},{"key":"B25","unstructured":"A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) [Internet]\n          \n          2019"},{"key":"B26","unstructured":"A Phase 3 Study of Selumetinib (NSC748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations [Internet]\n          \n          2020"},{"key":"B27","unstructured":"Phase I\/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion\/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults [Internet]\n          \n          2019"},{"key":"B28","unstructured":"Nivolumab and Tovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults [Internet]\n          \n          2022"},{"key":"B29","unstructured":"Phase 2 Study of the MEK Inhibitor MEKTOVI\n          \n          2022"},{"key":"B30","unstructured":"SJ901: Phase 1\/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1\/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma [Internet]\n          \n          2021"},{"key":"B31","unstructured":"LOGGIC\/FIREFLY-2: a Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy [Internet]\n          \n          2022"},{"key":"B32","unstructured":"A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK\/ERK Pathway [Internet]\n          \n          2017"},{"key":"B33","unstructured":"A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion [Internet]\n          \n          2020"},{"key":"B34","unstructured":"PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1\/2\/3 or ROS1-FUSED CNS Tumors (GLOBOTRK) [Internet]\n          \n          2024"},{"key":"B35","unstructured":"A Phase 1\/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or\u00a0Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations [Internet]\n          \n          2019"},{"key":"B36","unstructured":"A Phase 1\/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling [Internet]\n          \n          2021"},{"key":"B37","unstructured":"A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations [Internet]\n          \n          2018"},{"key":"B38","unstructured":"PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors [Internet]\n          \n          2021"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae031","article-title":"ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma","volume":"26","author":"Arrillaga-Romany","year":"2024","journal-title":"Neuro Oncol"},{"key":"B40","unstructured":"PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade Gliomas [Internet]\n          \n          2020"},{"key":"B41","unstructured":"A Pilot Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma [Internet]\n          \n          2021"},{"key":"B42","unstructured":"A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression [Internet]\n          \n          2021"},{"key":"B43","unstructured":"PhaseII Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed With HGG Including DIPG, Which Harbor Alterations of the Cell Cycle and\/or PI3K\/mTOR Pathways [Internet]\n          \n          2023"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33656","article-title":"BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas","volume":"118","author":"Pfister","year":"2008","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq007","article-title":"Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas","volume":"12","author":"Dougherty","year":"2010","journal-title":"Neuro Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00054","article-title":"Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas","volume":"5","author":"Penman","year":"2015","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s40478-024-01838-4","article-title":"Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated Malignant progression","volume":"12","author":"Apps","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1120-y","article-title":"BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma","volume":"125","author":"Dahiya","year":"2013","journal-title":"Acta Neuropathol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3572","article-title":"A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors","volume":"25","author":"Kieran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v11i21","article-title":"Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)","volume":"11","author":"Nicolaides","year":"2020","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00298.#91","article-title":"Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition","volume":"4","author":"Nobre","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1503","article-title":"FDA approval summary: dabrafenib in combination with trametinib for BRAFV600E mutation-positive low-grade glioma","volume":"30","author":"Barbato","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac096","article-title":"Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma","volume":"24","author":"Rosenberg","year":"2022","journal-title":"Neuro Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now282","article-title":"A phase i trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: A Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro-Oncology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.5.850","article-title":"Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood","volume":"11","author":"Packer","year":"1993","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1200\/JCO.2022.40.16_suppl.2042","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway","volume":"40","author":"Perreault","year":"2022","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7030860","article-title":"Targeting RTK signaling pathways in cancer","volume":"7","author":"Regad","year":"2015","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"vdab133","DOI":"10.1093\/noajnl\/vdab133","article-title":"Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter","volume":"3","author":"Qin","year":"2021","journal-title":"Neurooncol Adv"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.12.019","article-title":"Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds","volume":"12","author":"Liu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.3390\/cancers13246251","article-title":"Therapeutic targets in diffuse midline gliomas\u2014An emerging landscape","volume":"13","author":"Hayden","year":"2021","journal-title":"Cancers"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922928","article-title":"Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine","volume":"12","author":"Schwark","year":"2022","journal-title":"Front Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v11i22","article-title":"Efficacy of osimertinib against EGFRvIII+ glioblastoma","volume":"11","author":"Chagoya","year":"2020","journal-title":"Oncotarget"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03834-3","article-title":"Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation","volume":"154","author":"Cardona","year":"2021","journal-title":"J Neurooncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"CNS43","DOI":"10.2217\/cns-2019-0014","article-title":"Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma","volume":"8","author":"Makhlin","year":"2019","journal-title":"CNS Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.26502\/jcsct.5079114","article-title":"Clinical experience using osimertinib in patients with recurrent Malignant gliomas containing EGFR alterations","volume":"5","author":"Abousaud","year":"2021","journal-title":"J Cancer Sci Clin Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11602","article-title":"Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma","volume":"7","author":"Koschmann","year":"2016","journal-title":"Oncotarget"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad073.168","article-title":"Hgg-19. Clinical response to the pdgfra\/kit inhibitor avapritinib in pediatric and young adult high-grade glioma patients with H3k27m or pdgfra genomic alterations","volume":"25","author":"Trissal","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab196.249","article-title":"Ctni-24. A phase 1\/2 study of avapritinib in pediatric patients with solid tumors dependent on kit or pdgfra signaling","volume":"23","author":"Chi","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"10007","DOI":"10.1200\/JCO.2023.41.16_suppl.10007","article-title":"Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B)","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/ijms21030753","article-title":"NTRK fusions in central nervous system tumors: A rare, but worthy target","volume":"21","author":"Gambella","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41467-019-12187-5","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin","year":"2019","journal-title":"Nat Commun"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0581","article-title":"Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions","volume":"31","author":"Lamoureux","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.162","article-title":"Trls-09. Connect1903: A pilot and surgical study of larotrectinib for treatment of children with newly diagnosed hgg with ntrk fusion (Nct04655404)","volume":"26","author":"Chi","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21935","article-title":"Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan","volume":"52","author":"Packer","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"6087","DOI":"10.3390\/cancers14246087","article-title":"Impact of bevacizumab on visual function, tumor size, and toxicity in pediatric progressive optic pathway glioma: A retrospective nationwide multicentre study","volume":"14","author":"Bennebroek","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e30668","DOI":"10.1002\/pbc.v70.12","article-title":"Visual outcomes after bevacizumab-based therapy for optic pathway glioma","volume":"70","author":"Siegel","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms13021886","article-title":"The mTOR signalling pathway in human cancer","volume":"13","author":"Populo","year":"2012","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01838","article-title":"Everolimus for children with recurrent or progressive low-grade glioma: results from the phase II PNOC001 trial","volume":"42","author":"Haas-Kogan","year":"2024","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa071","article-title":"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study","volume":"22","author":"Ullrich","year":"2020","journal-title":"Neuro Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170329","article-title":"PI3K\/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma","volume":"134","author":"Duchatel","year":"2024","journal-title":"J Clin Invest"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0186","article-title":"ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma","volume":"83","author":"Jackson","year":"2023","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/cancers15041268","article-title":"Molecular heterogeneity in BRAF-mutant gliomas: diagnostic, prognostic, and therapeutic implications","volume":"15","author":"Lhermitte","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1837-8","article-title":"Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations","volume":"136","author":"Reinhardt","year":"2018","journal-title":"Acta Neuropathol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03864-9","article-title":"CNS penetration of the CDK4\/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors","volume":"84","author":"Patel","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2016.1278095","article-title":"Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies","volume":"12","author":"Maury","year":"2017","journal-title":"Epigenetics"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17837","article-title":"A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma","volume":"8","author":"Arrillaga-Romany","year":"2017","journal-title":"Oncotarget"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001826","article-title":"Central nervous system distribution of panobinostat in preclinical models to guide dosing for pediatric brain tumors","volume":"387","author":"Zhang","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad105","article-title":"PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"25","author":"Mueller","year":"2023","journal-title":"Neuro Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0394","article-title":"Fimepinostat impairs NF-kappaB and PI3K\/AKT signaling and enhances gemcitabine efficacy in H3K27M-mutated diffuse intrinsic pontine glioma","volume":"84","author":"Wang","year":"2023","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1135404","article-title":"Epigenetics and immune cells in medulloblastoma","volume":"14","author":"Gorini","year":"2023","journal-title":"Front Genet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2014.04.004","article-title":"Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth","volume":"207","author":"Kim","year":"2014","journal-title":"Cancer Genet"},{"key":"B114","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3390\/cells10113135","article-title":"Hedgehog pathway inhibitors against tumor microenvironment","volume":"10","author":"Gampala","year":"2021","journal-title":"Cells"},{"key":"B115","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/cancers11040538","article-title":"Next-generation hedgehog\/GLI pathway inhibitors for cancer therapy","volume":"11","author":"Peer","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.1591","article-title":"Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20619","article-title":"Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor","volume":"8","author":"Robinson","year":"2017","journal-title":"Oncotarget"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902903","article-title":"Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449","volume":"361","author":"Rudin","year":"2009","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.673154","article-title":"GLI1: A therapeutic target for cancer","volume":"11","author":"Avery","year":"2021","journal-title":"Front Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31110534","article-title":"Expansion of an academic molecular tumor board to enhance access to biomarker-driven trials and therapies in the rural Southeastern United States","volume":"31","author":"Kumar","year":"2024","journal-title":"Curr Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0803","article-title":"Upfront biology-guided therapy in diffuse intrinsic pontine glioma: therapeutic, molecular, and biomarker outcomes from PNOC003","volume":"28","author":"Kline","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v145.7","article-title":"A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium","volume":"145","author":"Mueller","year":"2019","journal-title":"Int J Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MPH.0000000000002964","article-title":"Retrospective comparison of targeted anticancer drugs predicted by the CNS-TAP tool versus those selected by a molecularly driven tumor board in children with DIPG","volume":"47","author":"Roberts","year":"2025","journal-title":"J Pediatr Hematol Oncol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.neo.2022.100861","article-title":"Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group","volume":"35","author":"Cooney","year":"2023","journal-title":"Neoplasia"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.157","article-title":"Trls-04. Early insights from pnoc027: personalized treatment approaches based on real-time drug screening and genomic testing in pediatric and adolescent patients with recurrent medulloblastoma","volume":"26","author":"Shatara","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2016.01.007","article-title":"Local delivery methods of therapeutic agents in the treatment of diffuse intrinsic brainstem gliomas","volume":"142","author":"Goodwin","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2012.04.012","article-title":"Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules","volume":"81","author":"Laine","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"B128","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2019.10.FOCUS19726","article-title":"Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives","volume":"48","author":"Beccaria","year":"2020","journal-title":"Neurosurg Focus"},{"key":"B129","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-020-03425-8","article-title":"Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors","volume":"151","author":"Beccaria","year":"2021","journal-title":"J Neurooncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1504803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:24:28Z","timestamp":1740727468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1504803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":129,"alternative-id":["10.3389\/fonc.2025.1504803"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1504803","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"1504803"}}